167 related articles for article (PubMed ID: 31023599)
1. Comprehensive geriatric assessment predicts azacitidine treatment duration and survival in older patients with myelodysplastic syndromes.
Molga A; Wall M; Chhetri R; Wee LY; Singhal D; Edwards S; Singhal N; Ross D; To LB; Caughey G; Shakib S; Germing U; To T; Hiwase D
J Geriatr Oncol; 2020 Jan; 11(1):114-120. PubMed ID: 31023599
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive geriatric assessment predicts mortality and adverse outcomes in hospitalized older adults.
Avelino-Silva TJ; Farfel JM; Curiati JA; Amaral JR; Campora F; Jacob-Filho W
BMC Geriatr; 2014 Dec; 14():129. PubMed ID: 25464932
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive geriatric assessment and its clinical impact in oncology.
Maas HA; Janssen-Heijnen ML; Olde Rikkert MG; Machteld Wymenga AN
Eur J Cancer; 2007 Oct; 43(15):2161-9. PubMed ID: 17855074
[TBL] [Abstract][Full Text] [Related]
4. Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study.
Mądry K; Lis K; Biecek P; Młynarczyk M; Rytel J; Górka M; Kacprzyk P; Dutka M; Rodzaj M; Bołkun Ł; Krochmalczyk D; Łątka E; Drozd-Sokołowska J; Waszczuk-Gajda A; Knopińska-Posłuszny W; Kopińska A; Subocz E; Masternak A; Guzicka-Kazimierczak R; Gil L; Machowicz R; Biliński J; Giebel S; Czerw T; Dwilewicz-Trojaczek J
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):264-274.e4. PubMed ID: 30898482
[TBL] [Abstract][Full Text] [Related]
5. Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).
Wehmeyer J; Zaiss M; Losem C; Schmitz S; Niemeier B; Harde J; Hannig CV; Harich HD; Müller J; Klausmann M; Tessen HW; Potthoff K
Eur J Haematol; 2018 Dec; 101(6):766-773. PubMed ID: 30091166
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive geriatric assessment in female elderly patients with Alzheimer disease and other types of dementia.
Riccio D; Solinas A; Astara G; Mantovani G
Arch Gerontol Geriatr; 2007; 44 Suppl 1():343-53. PubMed ID: 17317473
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study.
Repetto L; Fratino L; Audisio RA; Venturino A; Gianni W; Vercelli M; Parodi S; Dal Lago D; Gioia F; Monfardini S; Aapro MS; Serraino D; Zagonel V
J Clin Oncol; 2002 Jan; 20(2):494-502. PubMed ID: 11786579
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of preventive in-home geriatric assessment in well functioning, community-dwelling older people: secondary analysis of a randomized trial.
Büla CJ; Bérod AC; Stuck AE; Alessi CA; Aronow HU; Santos-Eggimann B; Rubenstein LZ; Beck JC
J Am Geriatr Soc; 1999 Apr; 47(4):389-95. PubMed ID: 10203111
[TBL] [Abstract][Full Text] [Related]
9. Use of comprehensive geriatric assessment (CGA) to define frailty in geriatric oncology: Searching for the best threshold. Cross-sectional study of 418 old patients with cancer evaluated in the Geriatric Frailty Clinic (G.F.C.) of Toulouse (France).
Bréchemier D; Sourdet S; Girard P; Steinmeyer Z; Mourey L; Gérard S; Balardy L
J Geriatr Oncol; 2019 Nov; 10(6):944-950. PubMed ID: 30956134
[TBL] [Abstract][Full Text] [Related]
10. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome.
Deschler B; Ihorst G; Platzbecker U; Germing U; März E; de Figuerido M; Fritzsche K; Haas P; Salih HR; Giagounidis A; Selleslag D; Labar B; de Witte T; Wijermans P; Lübbert M
Haematologica; 2013 Feb; 98(2):208-16. PubMed ID: 22875615
[TBL] [Abstract][Full Text] [Related]
11. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
12. Low serum vitamin D levels are associated with shorter survival after first-line azacitidine treatment in patients with myelodysplastic syndrome and secondary oligoblastic acute myeloid leukemia.
Radujkovic A; Schnitzler P; Ho AD; Dreger P; Luft T
Clin Nutr; 2017 Apr; 36(2):542-551. PubMed ID: 26899917
[TBL] [Abstract][Full Text] [Related]
13. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
Alhan C; Westers TM; van der Helm LH; Eeltink C; Huls G; Witte BI; Buchi F; Santini V; Ossenkoppele GJ; van de Loosdrecht AA
Cytometry B Clin Cytom; 2014 May; 86(3):207-15. PubMed ID: 24474614
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Geriatric Assessment in Older Patients with Diabetes Mellitus in Hanoi, Vietnam.
Vu HTT; Nguyen TTH; Le TA; Nguyen TX; Nguyen HTT; Nguyen TN; Pham T; Nguyen AT
Gerontology; 2022; 68(10):1132-1138. PubMed ID: 35078202
[TBL] [Abstract][Full Text] [Related]
15. Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.
Voso MT; Niscola P; Piciocchi A; Fianchi L; Maurillo L; Musto P; Pagano L; Mansueto G; Criscuolo M; Aloe-Spiriti MA; Buccisano F; Venditti A; Tendas A; Piccioni AL; Zini G; Latagliata R; Filardi N; Fragasso A; Fenu S; Breccia M;
Eur J Haematol; 2016 Apr; 96(4):344-51. PubMed ID: 26018238
[TBL] [Abstract][Full Text] [Related]
16. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.
Fenaux P; Ades L
Leuk Res; 2009 Dec; 33 Suppl 2():S7-11. PubMed ID: 20004796
[TBL] [Abstract][Full Text] [Related]
17. [The usage of comprehensive geriatric assessment in elderly patients with acute myeloid leukemia: a multicenter, prospective study].
Wu Q; Fu R; Zhao MF; Ma YG; Jiang H; Hu LD; Jing Y; Liu H; Wang LR; Su L; Zhang YQ; Zhou CL; Zhang Y; Ren HY; Jiang B; Zhou HB; Kang L; Zhang L; Zhou DB; Li J
Zhonghua Xue Ye Xue Za Zhi; 2019 Jan; 40(1):35-39. PubMed ID: 30704226
[No Abstract] [Full Text] [Related]
18. Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes.
Papadopoulos V; Diamantopoulos PT; Papageorgiou SG; Papoutselis M; Vrachiolias G; Pappa V; Galanopoulos AG; Vassilakopoulos TP; Hatzimichael E; Zikos P; Papadaki HA; Bouchla A; Panayiotidis P; Megalakaki A; Papaioannou M; Liapis K; Dryllis G; Tsokanas D; Kourakli A; Symeonidis A; Viniou NA; Kotsianidis I
Hematol Oncol; 2020 Oct; 38(4):541-553. PubMed ID: 32495951
[TBL] [Abstract][Full Text] [Related]
19. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of the Fibrinogen-Albumin Ratio Index in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine.
Akimoto M; Sakurai A; Nishiyama-Fujita Y; Ito C; Aisa Y; Nakazato T
Ann Hematol; 2021 Apr; 100(4):953-957. PubMed ID: 33521864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
